GlaxoSmithKline Pharmaceuticals · NSE: GLAXO · BSE: 500660
Q4 FY21 results · Jan–Mar 2021
GlaxoSmithKline Pharmaceuticals reported revenue from operations of ₹813.75 crore (up 4.9% from Q4 FY20) and net profit of ₹14.33 crore (down 89.6% from Q4 FY20) for Q4 FY21 (Jan–Mar 2021), on a consolidated basis.
| Item | Q4 FY21 | Q4 FY20 | YoY | Q3 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 813.75 | 775.80 | +4.9% | 857.20 | −5.1% |
| Other income | 29.60 | 15.82 | +87.1% | 14.02 | +111.1% |
| Total income | 843.35 | 791.62 | +6.5% | 871.22 | −3.2% |
| Profit before tax | 63.01 | 176.55 | −64.3% | 211.41 | −70.2% |
| Net profit for the period | 14.33 | 138.07 | −89.6% | 156.51 | −90.8% |
| EPS, basic (₹) | 0.85 | 8.15 | −89.6% | 9.24 | −90.8% |
| Net margin (%) | 1.8 | 17.8 | 18.3 |
| Item | Q4 FY21 | Q4 FY20 | YoY | Q3 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 807.27 | 775.88 | +4.0% | 858.42 | −6.0% |
| Other income | 29.61 | 15.16 | +95.4% | 13.87 | +113.5% |
| Total income | 836.88 | 791.04 | +5.8% | 872.29 | −4.1% |
| Profit before tax | 60.92 | 176.41 | −65.5% | 212.54 | −71.3% |
| Net profit for the period | 12.74 | 137.94 | −90.8% | 157.35 | −91.9% |
| EPS, basic (₹) | 0.75 | 8.14 | −90.8% | 9.29 | −91.9% |
| Net margin (%) | 1.6 | 17.8 | 18.3 |
Consolidated
- Filed with BSE
- 19 May 2021, 11:09 IST
- Board meeting
- 18 May 2021
- Period
- 01 Jan 2021 to 31 Mar 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 19 May 2021, 11:09 IST
- Board meeting
- 18 May 2021
- Period
- 01 Jan 2021 to 31 Mar 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE